Vasoactive intestinal peptide is a neuropeptide with broad anti-inflammatory, vasodilatory, and immunomodulatory properties being investigated in autoimmune and pulmonary diseases.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Vasoactive Intestinal Peptide — almost universally shortened to VIP — is a 28-amino acid neuropeptide that belongs to the secretin/glucagon superfamily. First isolated in 1970 by Said and Mutt from porcine intestinal tissue, VIP was originally named for its potent vasodilatory activity. That early framing turned out to be only a small part of the story. Decades of subsequent research revealed that VIP is one of the most broadly distributed and functionally versatile signaling molecules in human biology.
Unlike peptides confined to a single tissue or organ, VIP is expressed throughout the central and peripheral nervous systems, the gastrointestinal tract, the respiratory tract, the reproductive system, and in resident immune cells including macrophages, T cells, mast cells, and dendritic cells. This ubiquity is a clue to its fundamental importance. VIP doesn’t do one job — it orchestrates communication across multiple organ systems simultaneously, functioning as a neurotransmitter, a neuromodulator, a hormone, and an immunoregulatory molecule depending on context.
From a structural standpoint, VIP shares meaningful sequence homology with secretin, glucagon, GIP, PACAP, and PHI. This family relationship isn’t merely academic: it explains why VIP signals through the same class of G protein-coupled receptors as several other regulatory peptides. VIP acts primarily through two receptor subtypes — VPAC1 and VPAC2 — both of which are coupled to Gs proteins and drive cyclic AMP (cAMP) elevation inside target cells. A third receptor, PAC1, binds VIP with lower affinity but with high affinity for the closely related peptide PACAP.
In the gut, VIP regulates smooth muscle relaxation, secretion, and blood flow. In the lungs, it bronchodilates and modulates airway inflammation. In the brain, it synchronizes circadian rhythms through its dense expression in the suprachiasmatic nucleus (SCN). In the immune system, it dampens pro-inflammatory cytokine production and promotes regulatory T-cell (Treg) differentiation — a property that has generated considerable clinical interest in autoimmune and inflammatory conditions.
Perhaps the most clinically relevant emerging application of VIP research involves CIRS — Chronic Inflammatory Response Syndrome — a multisystem condition associated with biotoxin exposure where VIP levels are found to be persistently suppressed. Restoring VIP signaling in this context has become a focus of exploratory treatment protocols, making VIP one of the more actively investigated neuropeptides in functional and integrative medicine. You can explore VIP alongside related compounds in the Peptide Database.
VIP’s primary mechanism of action runs through two receptor subtypes: VPAC1 and VPAC2. Both are class B G protein-coupled receptors linked to heterotrimeric Gs proteins. When VIP binds either receptor, it triggers dissociation of the Gs alpha subunit, which then activates adenylyl cyclase. The result is a rapid intracellular rise in cyclic AMP (cAMP), which in turn activates protein kinase A (PKA). PKA phosphorylates a wide range of downstream targets depending on the cell type — smooth muscle relaxation proteins in vascular tissue, ion channel regulators in airway epithelium, and transcription factors like CREB in neurons and immune cells.
VPAC1 is expressed constitutively in most tissues including lymphocytes, lung, liver, and brain. VPAC2 has a more restricted distribution with notable expression in smooth muscle, pancreatic islets, and certain brain regions including the SCN. The differential expression of these two receptor subtypes explains why VIP can have tissue-specific effects that may seem contradictory — activating secretion in one location while suppressing inflammation in another. In immune cells, the PKA-CREB axis downstream of VIP receptor activation directly suppresses NF-κB nuclear translocation, which is a central node for pro-inflammatory gene transcription.
One of the most consequential immunological actions of VIP is its ability to interfere with NF-κB signaling — the master transcriptional regulator of inflammatory gene expression. In macrophages, dendritic cells, and T cells stimulated by LPS or other danger signals, VIP blunts IκB kinase (IKK) activity. IKK is the kinase complex responsible for phosphorylating and degrading IκB, the inhibitor that normally keeps NF-κB sequestered in the cytoplasm. By reducing IKK activity (via cAMP/PKA signaling), VIP preserves higher levels of IκB and keeps NF-κB out of the nucleus — thereby reducing transcription of TNF-alpha, IL-1 beta, IL-6, IL-12, and other cytokines whose promoters depend on NF-κB binding.
Simultaneously, VIP upregulates interleukin-10 (IL-10) production through CREB-mediated transcription. IL-10 is a potent anti-inflammatory cytokine that feeds back to further suppress macrophage activation and promote regulatory T-cell function. VIP also increases expression of Foxp3, the master transcription factor of Tregs, effectively programming naive CD4+ T cells away from inflammatory Th1 and Th17 phenotypes. This dual action — suppressing the pro-inflammatory axis while amplifying the regulatory axis — makes VIP’s immunological profile uniquely broad and potentially well-suited to conditions driven by chronic, dysregulated inflammation.
Within the suprachiasmatic nucleus — the master circadian clock — VIP is the dominant neuropeptide used by a subset of neurons to synchronize the oscillatory activity of the entire SCN network. Individual SCN neurons contain autonomous molecular clocks based on transcription-translation feedback loops involving CLOCK, BMAL1, PER, and CRY proteins. Without cell-to-cell communication, these individual clocks drift out of phase with each other. VIP, released from the ventrolateral SCN in response to light input from the retinohypothalamic tract, binds VPAC2 on neighboring neurons and resets their phase through cAMP-PKA signaling. This synchronization function is so fundamental that VIP-null mice or VPAC2-null mice have severely fragmented and arrhythmic activity patterns. Beyond the SCN itself, VIP coordinates the timing of peripheral organ clocks — including those in the liver, gut, immune system, and adrenal glands — through downstream neuroendocrine outputs. Disruptions in this synchronization system have been linked to metabolic dysfunction, impaired immune timing, and increased cancer risk.
Chronic Inflammatory Response Syndrome (CIRS), as characterized by physician and researcher Dr. Ritchie Shoemaker, is a multisystem illness triggered by exposure to biotoxins — most commonly water-damaged building mold, but also toxins from cyanobacteria, dinoflagellates (as in Pfiesteria or Ciguatera exposure), and Lyme disease co-infections. In susceptible individuals with certain HLA-DR haplotypes, biotoxins are not adequately cleared and trigger a persistent cascade of innate immune activation, leading to chronically elevated cytokines, reduced MSH (alpha-melanocyte stimulating hormone), suppressed VIP levels, VEGF dysregulation, and measurable changes in brain structure on NeuroQuant volumetric MRI.
VIP’s role in the CIRS protocol stems from two observations: first, that circulating VIP levels are measurably reduced in CIRS patients; and second, that intranasal VIP administration appears to correct a broad range of downstream inflammatory markers and symptom clusters. In Shoemaker’s published case series, intranasal VIP (administered as a compounded nasal spray at doses of 50 micrograms four times daily) was associated with normalization of TGF-beta-1, reduction of MMP-9, improvement in VEGF, and patient-reported improvements in cognition, fatigue, and sleep. Critically, VIP is used only after the building exposure has been removed and other inflammatory markers have been partially corrected — using it while still in a toxic environment is considered counterproductive. While randomized controlled trials remain limited, the mechanistic rationale is strong given VIP’s documented suppression of innate immune cytokines.
Pulmonary arterial hypertension (PAH) is a progressive and often fatal condition characterized by elevated pressure in the pulmonary vasculature, right ventricular hypertrophy, and eventual heart failure. VIP is abundantly expressed in pulmonary nerve fibers, and its vasodilatory, anti-proliferative, and anti-inflammatory properties make it mechanistically attractive as a PAH therapy. Research has shown that VIP-knockout mice spontaneously develop PAH-like pulmonary vascular remodeling, suggesting endogenous VIP plays a protective role in maintaining pulmonary vascular homeostasis.
A clinical study by Petkov et al. published in the New England Journal of Medicine reported that inhaled VIP (100 micrograms per administration) significantly improved hemodynamic parameters and exercise tolerance in PAH patients compared to placebo. The peptide reduced mean pulmonary arterial pressure, improved cardiac output, and decreased pulmonary vascular resistance. Subsequent research has worked to improve VIP’s short half-life (approximately 2 minutes in plasma) through formulation strategies including nanoparticles, liposomal encapsulation, and longer-acting analogs. While VIP has not yet achieved regulatory approval for PAH, it remains an active area of pharmaceutical development.
The neuroprotective potential of VIP has been studied across a range of neurodegenerative models. In Parkinson’s disease models, VIP protects dopaminergic neurons in the substantia nigra from MPTP-induced toxicity through both direct mechanisms (reducing mitochondrial oxidative stress) and indirect mechanisms (suppressing microglial activation and TNF-alpha release). VIP also stimulates astroglial release of ADNP (activity-dependent neuroprotective protein) and PACAP, which are separately known to support neuronal survival.
In Alzheimer’s disease contexts, VIP reduces beta-amyloid-induced toxicity in hippocampal neurons and has been shown to decrease tau hyperphosphorylation by inhibiting GSK-3 beta activity — a kinase that phosphorylates tau at multiple pathological sites. VIP also promotes expression of BDNF and NGF, neurotrophins that support synaptic plasticity and neuronal maintenance. Animal models of VIP deficiency display accelerated cognitive decline under amyloid burden, reinforcing the idea that VIP acts as an endogenous neuroprotective buffer. Human studies on VIP levels in AD patients are limited but suggest reduced VIP-immunoreactive fibers in hippocampal tissue in affected brains.
The Treg-promoting, NF-κB-suppressing profile of VIP has generated interest in autoimmune conditions where chronic T-cell-driven inflammation causes tissue damage. In experimental autoimmune models including collagen-induced arthritis (the standard rodent model of rheumatoid arthritis), VIP administration reduced joint inflammation, decreased synovial cytokine levels, and increased the proportion of Foxp3+ regulatory T cells in lymphoid tissue. Researchers identified VIP-producing immune cells within inflamed synovium, suggesting the peptide plays an endogenous regulatory role in joint inflammation.
In inflammatory bowel disease models — including both DSS-induced colitis and the IL-10 knockout spontaneous colitis model — VIP reduced mucosal inflammation, improved epithelial barrier integrity, and modulated the balance between Th17 and Treg cells. Interestingly, oral and intranasal delivery routes for VIP have been explored specifically for IBD to take advantage of mucosal immune regulation without requiring systemic administration. The potential synergy between VIP’s mechanisms and those of other gut-targeting peptides like KPV (covered separately) is an area of ongoing interest.
VIP plays several underappreciated roles in reproductive biology. In the hypothalamus, VIP stimulates pulsatile GnRH release, and in the pituitary, it directly stimulates prolactin secretion — a function shared with its secretin-family relative PACAP. In the ovary, VIP regulates granulosa cell steroidogenesis and follicular development. In the uterus, VIP-producing nerves modulate myometrial tone, endometrial blood flow, and implantation. Some research has examined VIP in the context of premature labor (VIP’s smooth muscle relaxation suppressing uterine contractions) and in polycystic ovary syndrome, where altered VIP-receptor signaling may contribute to the hormonal dysregulation characteristic of the condition.
In the context of CIRS protocols, intranasal VIP is the delivery method with the most clinical documentation. Shoemaker’s protocol typically begins with a test dose of 50 micrograms (roughly 0.1 mL of a 500 mcg/mL compounded formulation) administered in one nostril. If no adverse reaction occurs, dosing is escalated to 50 micrograms four times daily, often as a nasal spray. The rationale for intranasal delivery is twofold: nasal mucosal absorption allows direct entry into the cerebrospinal fluid compartment via olfactory nerve pathways, and the nasal-associated lymphoid tissue (NALT) is an important site of immune regulation where VIP receptors are highly expressed. Nasal VIP compounded preparations require pharmaceutical-grade sourcing and typically have a limited shelf life requiring refrigeration.
For pulmonary arterial hypertension research, VIP has been studied as an inhaled aerosol. The Petkov clinical trial used 100 micrograms per inhalation administered via nebulizer. This route preferentially delivers VIP to pulmonary vascular smooth muscle and airway epithelium while limiting systemic exposure. The short half-life of VIP in the circulation (approximately 2 minutes) is less of a concern with inhalation because the compound acts locally before being rapidly degraded by dipeptidyl peptidase IV (DPP-IV) and other peptidases. Inhaled delivery has also been studied for asthma and COPD, where VIP’s bronchodilatory and anti-inflammatory properties could be directly applied to airway tissue.
Intravenous or subcutaneous systemic administration of VIP is largely confined to research settings due to the peptide’s extremely short plasma half-life. When administered IV, VIP is cleared within minutes primarily by endothelial peptidases and DPP-IV. Subcutaneous injection similarly results in rapid degradation. Researchers have addressed this by developing PEGylated VIP analogs, liposomal formulations, and VIP-conjugated nanoparticles that extend circulation time and improve tissue targeting. These modified forms are not yet clinically available but represent the direction of pharmaceutical development for conditions where systemic VIP action is desired. Users interested in dosage calculations for research contexts can consult the Peptide Dosage Calculators.
Within the structured CIRS treatment hierarchy, VIP is not a first-line intervention. It is positioned as a late-stage treatment deployed only after successful completion of earlier protocol steps — including removal from the toxic building, cholestyramine or welchol binding, VCS (visual contrast sensitivity) normalization, correction of MMP-9, VEGF, and C4a, and treatment of any co-infections. The reasoning is that VIP will be ineffective or potentially counterproductive if the underlying inflammatory drivers have not been addressed. When used appropriately, treatment duration typically spans several months with periodic reassessment of inflammatory biomarkers. Ongoing guidance from a CIRS-literate physician is considered essential. The AI Peptide Coach can help contextualize VIP within broader research protocols.
VIP has a generally favorable tolerability profile in the research literature, particularly at the doses used in CIRS protocols. The most commonly reported side effects with intranasal VIP include nasal irritation or burning, transient flushing (consistent with its vasodilatory properties), mild headache, and occasional nausea. These effects are typically mild and tend to diminish with continued use. The facial flushing is mechanistically expected given VIP’s role in vasodilation and is not considered a sign of danger unless accompanied by cardiovascular symptoms. In the inhaled PAH studies, transient decreases in systemic blood pressure were observed at higher doses, reflecting the systemic vasodilatory effects when VIP enters the circulation via pulmonary absorption.
One important safety consideration in the CIRS protocol context is the requirement for prior removal of biotoxin exposure. If VIP is administered to someone who is still being exposed to mold or other biotoxins, clinical reports from practitioners suggest it can worsen inflammatory symptoms — a phenomenon sometimes described as a paradoxical reaction. This is believed to occur because VIP’s immunomodulatory effects cannot overcome ongoing innate immune activation driven by persistent toxin exposure.
VIP’s vasodilatory effects may be additive with antihypertensive medications, phosphodiesterase inhibitors (like sildenafil), or other vasodilatory peptides. Caution is warranted in patients on blood pressure-lowering agents, particularly when using inhaled or systemic routes. VIP’s prolactin-stimulating effects could theoretically interact with dopamine agonists used to treat hyperprolactinemia. Because VIP modulates T-cell polarization and cytokine production, there is theoretical concern about interactions with immunosuppressive medications — though this has not been well characterized in human studies. As with all peptides, sourcing quality matters significantly, as contaminants in poorly manufactured compounded preparations represent their own safety risk independent of VIP’s pharmacology.
VIP is not recommended during pregnancy due to its vasoactive properties and potential effects on uterine tone and placental circulation. Its prolactin-stimulating effects argue for caution in patients with prolactinomas or hormone-sensitive conditions. Individuals with low blood pressure or autonomic dysfunction may be more susceptible to VIP-induced vasodilation and should use lower doses with careful monitoring. There are no well-characterized long-term safety studies in humans for VIP administration beyond the existing clinical trial data, which limits conclusions about extended use. As with all peptide research, the framework for use should involve medical supervision, careful baseline biomarker assessment, and ongoing monitoring of relevant parameters.
Most peptides used in research contexts have a fairly narrow mechanism — a specific receptor, a specific tissue, a specific effect. VIP is unusual because it operates across the nervous system, the immune system, the cardiovascular system, and the gut simultaneously. Its VPAC1/VPAC2 receptor distribution is extraordinarily broad, which means a single dose can affect circadian timing in the brain, cytokine production in macrophages, and vascular tone in the lungs at the same time. That breadth is what makes it particularly interesting for complex multisystem conditions like CIRS, but it also means the pharmacology is more complicated to predict than a more targeted peptide.
Yes. Compounded VIP preparations — particularly nasal sprays — are peptide-based and susceptible to degradation at room temperature. Most compounding pharmacies package VIP nasal sprays with refrigeration instructions and specify a relatively short beyond-use date (typically 30–60 days). VIP should be protected from light and heat and should never be left at room temperature for extended periods. If a preparation has become cloudy, discolored, or developed particulates, it should not be used. Reconstituted peptide solutions for research use follow similar storage principles as other fragile peptides.
In CIRS protocols, VIP is positioned at the end of a sequential treatment hierarchy rather than combined freely with other agents. Outside of that specific context, some researchers have explored VIP’s potential synergy with other anti-inflammatory or neuroprotective peptides, but rigorous human data on combinations is sparse. Given VIP’s vasodilatory effects, pairing it with other vasodilatory compounds warrants caution. In terms of immune modulation, VIP’s Treg-promoting and cytokine-suppressing properties are conceptually complementary to peptides like KPV and BPC-157, though combined use has not been formally studied in humans.
The mechanistic explanation for suppressed VIP in CIRS is not entirely resolved, but the leading hypothesis involves the chronic cytokine environment — particularly elevated TGF-beta-1 and MMP-9 — that characterizes the condition. Elevated MMP-9 and other inflammatory proteases can degrade neuropeptides directly. Additionally, chronic hypothalamic inflammation and the downstream suppression of MSH (alpha-MSH) that occurs in CIRS may impair the regulation of VIP-producing neurons. VIP and MSH appear to have reciprocally supportive relationships in the hypothalamus, so suppression of one tends to correlate with suppression of the other. Low VIP in CIRS is not considered an isolated finding but rather part of a broader disruption of neuropeptide homeostasis.
They share the same active peptide but differ in pharmacokinetics, bioavailability, and target tissue distribution. Intranasal VIP has the advantage of direct access to the CNS via olfactory pathways and direct effect on NALT immune cells, while systemic injection delivers VIP to the circulation where its half-life is only about 2 minutes. For CIRS applications, intranasal delivery is specifically preferred because the target effects are both central (brain inflammation, circadian regulation) and mucosal (immune modulation). For PAH research, inhalation targets pulmonary tissue directly. The route of administration should be matched to the intended application rather than treated as interchangeable.
Based on practitioner reports and Shoemaker’s published case series, patients who respond to VIP typically begin noticing improvements in energy, sleep quality, and cognitive clarity within the first 1–4 weeks of use. Measurable changes in inflammatory biomarkers — TGF-beta-1, VEGF, MMP-9 — may be detected within 4–8 weeks. NeuroQuant brain volume improvements, when they occur, are typically assessed at 3–6 months. Response is highly variable depending on where the patient is in the CIRS treatment hierarchy, how thoroughly earlier steps have been completed, and individual genetic factors including HLA-DR haplotype. Non-responders should be evaluated for ongoing exposure or incomplete prior treatment steps rather than simply increasing the VIP dose.
The Peptide Database contains detailed profiles of VIP alongside related compounds in the secretin/glucagon superfamily. For personalized guidance on how VIP might fit into a broader research or wellness context, the AI Peptide Coach is a useful resource. If you need to work out dosing parameters for research purposes, the Dosage Calculators can help with volume and concentration calculations.
No, though the two peptides are closely related. PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) exists in 27- and 38-amino acid forms and shares significant sequence homology with VIP. Both bind VPAC1 and VPAC2, but PACAP additionally binds PAC1 with very high affinity — a receptor that VIP binds only weakly. PAC1 has distinct downstream signaling through both Gs and Gq pathways, which gives PACAP effects that VIP does not produce, including different neurological and endocrine actions. PACAP tends to be more potent than VIP at shared receptors and has somewhat different distribution in the brain and periphery. They are complementary but not interchangeable.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.